Peptide raw materials for qualified B2B buyers. Custom peptide synthesis and scale-up review. Lyophilized powder OEM / ODM enquiries. Batch-specific specifications and documents on request.

Enquiries: info@hytanpeptides.com
Peptide Raw Material Request a Quote
Technical guide

Private-Label Peptide Powder: The Specification-to-Release Handoff

Packaging and quality teams reviewing powder samples and carton proofs; illustrative editorial image

Private-label projects often begin with a promising sample and a packaging concept. Commercial problems appear when the approved sample, purchase specification and printed pack describe different things. A clear handoff records what was approved, by whom, and what evidence must be checked before the first lot ships.

Freeze the technical brief before artwork

Write down the material identity, supplied form, target quantity, intended end use and destination markets. Decide which attributes are acceptance criteria and which are development targets. If the product is a cosmetic ingredient, a finished cosmetic or a research material, keep the classification explicit. Label wording and documentation depend on that distinction. See our identity guide for the fields that should travel with the brief.

Separate approval gates

Sample and specification

Record the sample lot, test data and any deviation accepted during evaluation. The approved commercial specification should state identity, tests, methods, limits and pack configuration. Approval of a laboratory sample does not silently approve a different salt form, concentration or pack for production.

Packaging and artwork

Assign an owner for text, translations, legal review and final artwork sign-off. The print proof should match the agreed product name, net content basis, lot coding area, storage instruction and destination requirements. Avoid adding unsubstantiated efficacy or regulatory claims to the carton. The FDA’s cosmetics labeling resources are useful for US cosmetic projects; other markets need their own review.

Production and release

Agree how the production lot links to raw-material lots, in-process checks, packaging records and final COA. Define who reviews a deviation, approves a change and releases the lot. The FDA cosmetic GMP checklist describes written production instructions, batch code marks and records covering materials, manufacturing and test results. Apply the relevant controls to the actual product category, rather than copying a generic checklist into an agreement.

A concise handoff file

  • Signed product brief and market classification.
  • Approved specification, analytical methods and sample reference.
  • Approved container, closure, pack sizes and artwork version.
  • Responsibilities for claim, label and destination-market review.
  • Change-notification rules and deviation decision owner.
  • Required lot documents, release criteria and shipping conditions.

Our OEM and custom project workflow can be scoped against this file. Send a project enquiry with the intended product category and deliverables so feasibility can be assessed before a commercial commitment.

Frequently asked questions

Does sample approval authorize production automatically?

No. Production should follow the approved commercial specification, pack and release plan. Any differences from the sample need explicit review.

Who approves the final label?

The agreement should name the responsible party for artwork, claims and destination-market legal review, with the final version recorded before print.

What should accompany a shipped lot?

The agreed documentation may include a lot-specific COA and other quality or shipment records. Its exact scope should be written into the purchase agreement.

Record the final approvals in one controlled handoff file so the first commercial lot can be compared with what the team actually signed off.

← More guides